Complement-Targeted Therapies in Glioblastoma: A Systematic Review
Chase M. Walton, Ben A. Strickland · 2026
Read Complement-Targeted Therapies in Glioblastoma: A Systematic Review by Chase M. Walton, Ben A. Strickland (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13510105.txt.
Description
Walton and Strickland reviewed in 2026 therapies that target the complement system in glioblastoma, the most common and deadly primary brain tumor in adults. Complement is a blood-borne defence network, but in this tumor it plays a double role. It aids attack on cancer cells while also sending calming signals that shield the tumor. The team graded 41 studies, from cell and animal work to patient observations.
Walton found most work clusters on a few targets, such as the C3b tagging step and the C5a signal and its receptor. Only five animal survival studies were alike enough to compare, and they were too different to pool. Certainty of evidence was rated very low, so the authors frame complement drugs as a hypothesis needing standard models and proper trials.
Catalog record
| CREATOR | Chase M. Walton, Ben A. Strickland |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |